BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that research underlying its EDP 10 project for the treatment of type 1 diabetes won the Hebrew University's prestigious Kaye Innovation Award for a researcher at the Hebrew University of Jerusalem. The research was performed by Dr. Chamutal Gur MD, currently a physician at the Hadassah Medical Institute.
Dr. Gur, under the supervision of Professor Ofer Mandelboim of the Hebrew University, Institute for Medical Research Israel Canada, Hadassah Medical School, studied the role of Natural Killer cells in autoimmune diseases. Her main project focused on the function of the NKp46 killer receptor in the development of type 1 diabetes. Dr. Gur and her colleagues have shown that a protein receptor called NKp46 present on Natural Killer cells has a critical role in the development of the disease in mice, and that inhibition of the receptor almost entirely prevented the development of diabetes.
This groundbreaking research is the basis for BioLineRx’s EDP-10 project, which is aimed at characterizing and developing efficient inhibitors of NKp46 for the prevention and possible treatment of type 1 diabetes. EDP-10 is being developed by BioLineRx in collaboration with Professor Mandelboim, Professor Yaacov Naparstek, Chairman of Medicine at Hadassah University Hospital and Professor of Medicine at the Hebrew University-Hadassah School of Medicine and Professor Angel Porgador, the Department of Microbiology and Immunology Faculty of Health Sciences at Ben Gurion University of the Negev, who recently published the findings of the collaborative research on the mode of action of NKp46 in the Journal of Immunology, a leading scientific journal.
"Type 1 diabetes is a highly prevalent autoimmune disease," said Dr. Kinneret Savitsky, CEO of BioLineRx. "Millions of people throughout the world suffer from this disease and need to inject insulin on a regular basis. We hope that our research will help to advance the EDP 10 molecules as a potential treatment for this debilitating disease.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV